Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4B | O94953 | 1/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MARK3 | P27448 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692017 | 0.98 | PARP1 (0.53) | PARP1KDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL243725 | 0.98 | PARP1 (0.53) | PARP1KDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL1159186 | 0.82 | PARP1 (0.53) | PARP1KDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL28693642 | 0.75 | CHEK1 (0.49) | PARP1KDM4CROCK2PRKACAPRKCD | |
| SCHEMBL1934489 | 0.74 | AURKA (0.46) | GSK3BJAK2AURKADAPK3ROCK2 | |
| SCHEMBL21224465 | 0.74 | PARP1 (0.52) | PARP1KDM4CKDM4AKDM4BKDM5C | |
| Bromide SCHEMBL27922950 | 0.71 | IMPDH2 (0.56) | GSK3BJAK2AURKADAPK3ROCK2 | |
| Bromide SCHEMBL2722104 | 0.71 | PDE3B (0.48) | PIM1MAPTPDE3BPDE3ADAO | |
| SCHEMBL3394071 | 0.71 | PARP1 (0.60) | PARP1KDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL13859948 | 0.70 | IMPDH2 (0.50) | PARP1KDM4CKDM4AKDM4BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2252613-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM, LLC (BM) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009105717-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | PARP1 3416/4885KDM4C 3813/4885KDM4A 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.